share_log

bluebird bio | 8-K: Current report

bluebird bio | 8-K: Current report

bluebird bio | 8-K：重大事件
美股SEC公告 ·  11/06 16:24

Moomoo AI 已提取核心訊息

On November 6, 2024, bluebird bio, Inc. conducted its 2024 Annual Meeting of Stockholders, where several key proposals were voted upon. The stockholders elected John O. Agwunobi, Elisabeth Leiderman, and Andrew Obenshain as Class II directors. Additionally, the stockholders approved the amendment and restatement of the 2023 Incentive Award Plan, increasing the number of shares authorized for issuance by 15 million to a total of 20.2 million. The compensation paid to the company's named executive officers was approved in a non-binding advisory vote. However, the proposal to amend the Certificate of Incorporation for officer exculpation did not receive the required votes for approval. The selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified. A proposal to adjourn the Annual Meeting to solicit additional proxies for the approval of certain proposals was also passed. The meeting was adjourned with respect to a proposal for a reverse stock split, with the reconvened meeting scheduled for December 4, 2024.
On November 6, 2024, bluebird bio, Inc. conducted its 2024 Annual Meeting of Stockholders, where several key proposals were voted upon. The stockholders elected John O. Agwunobi, Elisabeth Leiderman, and Andrew Obenshain as Class II directors. Additionally, the stockholders approved the amendment and restatement of the 2023 Incentive Award Plan, increasing the number of shares authorized for issuance by 15 million to a total of 20.2 million. The compensation paid to the company's named executive officers was approved in a non-binding advisory vote. However, the proposal to amend the Certificate of Incorporation for officer exculpation did not receive the required votes for approval. The selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified. A proposal to adjourn the Annual Meeting to solicit additional proxies for the approval of certain proposals was also passed. The meeting was adjourned with respect to a proposal for a reverse stock split, with the reconvened meeting scheduled for December 4, 2024.
2024年11月6日，藍鳥生物公司進行了2024年股東大會，就幾項重要提案進行了投票表決。股東選舉了John O. Agwunobi、Elisabeth Leiderman和Andrew Obenshain爲II類董事。此外，股東批准修訂2023年激勵獎勵計劃，並將發行授權股份數量增加至2020萬，增加了1500萬。公司董事高管的薪酬已在非約束性諮詢性投票中獲得批准。然而，關於修改公司章程以豁免公司董事責任的提案未獲得所需的批准票數。選舉Ernst & Young LLP爲截至2024年12月31日的財政年度的獨立註冊會計事務所得到認可。另外，提出將年度股東大會延期，以就某些提案的批准再徵集額外代理的提案也獲得通過。關於股票逆向拆分提案的會議已被延期，重新召開的會議定於2024年12月4日舉行。
2024年11月6日，藍鳥生物公司進行了2024年股東大會，就幾項重要提案進行了投票表決。股東選舉了John O. Agwunobi、Elisabeth Leiderman和Andrew Obenshain爲II類董事。此外，股東批准修訂2023年激勵獎勵計劃，並將發行授權股份數量增加至2020萬，增加了1500萬。公司董事高管的薪酬已在非約束性諮詢性投票中獲得批准。然而，關於修改公司章程以豁免公司董事責任的提案未獲得所需的批准票數。選舉Ernst & Young LLP爲截至2024年12月31日的財政年度的獨立註冊會計事務所得到認可。另外，提出將年度股東大會延期，以就某些提案的批准再徵集額外代理的提案也獲得通過。關於股票逆向拆分提案的會議已被延期，重新召開的會議定於2024年12月4日舉行。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間